The Lynx Group

Bernard Escudier, MD


Authored Items

Cabozantinib Improves Standard of Care for Second-Line Treatment of Advanced Kidney Cancer

March 2016, Vol. 5, No. 2 - Genitourinary Cancers Symposium

Cabozantinib achieved superior progression-free survival (PFS) versus standard treatment with everolimus in patients with previously treated advanced kidney cancer in an updated analysis of the phase 3 METEOR trial reported at the Genitourinary Cancers Symposium. In addition, a strong trend toward overall survival (OS) favored cabozantinib at an interim analysis, [ Read More ]

Sign me up!